Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Regeneron Pharmaceuticals Stock Quote

Regeneron Pharmaceuticals (NASDAQ: REGN)

Price as of July 22, 2024, 4:00 p.m. ET

Regeneron Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
REGN +45.62% +241.08% +27.81% +4,964%
S&P +22.66% +84.28% +13.00% +1,366%

Regeneron Pharmaceuticals Company Info

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

News & Analysis

The Fool has written over 600 articles on Regeneron Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.